|
|
|
| home > white papers > Delivering Fit For Purpose Biomanufacturing CHO Cell Lines - Fujifilm Diosynth Biotechnologies |
|
|
 WHITE PAPERS |
|
Fujifilm Diosynth Biotechnologies
|
|
Delivering Fit For Purpose Biomanufacturing CHO Cell Lines
|
|
The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
PCI Pharma Services Announces Acquisition of Millmount Healthcare
Philadelphia, PA – October 2, 2017 – Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the acquisition of pharmaceutical and healthcare contract packaging services provider Millmount Healthcare, located near Dublin, Ireland.
More info >> |
|
 |
White Papers |
 |
|
Crunch Time: The Impact of Serialisation Requirements on Packaging Operations
PCI Pharma Services
The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >> |
|
 |
Industry Events |
 |
Clinical Trial Supply Forum 2018
22-24 January 2018, London, UK
In the constantly changing
environment of Clinical Trial Supply, cost efficiency, end to end visibility,
logistics and managing complex pipelines are STILL crucial elements that need
addressing!
More info >> |
|
|
|
